Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

BACKGROUND: Anti-CD19 CAR T cell therapy has demonstrated high response rates in patients with relapsed or refractory (r/r) B cell malignancies but is associated with significant toxicity. Cytokine release syndrome (CRS) is the most significant complication associated with CAR T cell therapy, and it...

Descripción completa

Detalles Bibliográficos
Autores principales: Porter, David, Frey, Noelle, Wood, Patricia A., Weng, Yanqiu, Grupp, Stephan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070/
https://www.ncbi.nlm.nih.gov/pubmed/29499750
http://dx.doi.org/10.1186/s13045-018-0571-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070/
https://www.ncbi.nlm.nih.gov/pubmed/29499750
http://dx.doi.org/10.1186/s13045-018-0571-y

Ejemplares similares